Zhejiang Orient Gene Biotech Co Ltd (688298) - Net Assets

Latest as of September 2025: CN¥6.49 Billion CNY ≈ $950.10 Million USD

Based on the latest financial reports, Zhejiang Orient Gene Biotech Co Ltd (688298) has net assets worth CN¥6.49 Billion CNY (≈ $950.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.51 Billion ≈ $1.10 Billion USD) and total liabilities (CN¥1.01 Billion ≈ $148.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688298 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥6.49 Billion
% of Total Assets	86.48%
Annual Growth Rate	69.71%
5-Year Change	177.04%
10-Year Change	N/A
Growth Volatility	277.82

Zhejiang Orient Gene Biotech Co Ltd - Net Assets Trend (2016–2024)

This chart illustrates how Zhejiang Orient Gene Biotech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Zhejiang Orient Gene Biotech Co Ltd asset portfolio for the complete picture of this company's asset base.

Annual Net Assets for Zhejiang Orient Gene Biotech Co Ltd (2016–2024)

The table below shows the annual net assets of Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2024. For live valuation and market cap data, see market value of Zhejiang Orient Gene Biotech Co Ltd.

Year	Net Assets	Change
2024-12-31	CN¥6.79 Billion ≈ $993.80 Million	-10.04%
2023-12-31	CN¥7.55 Billion ≈ $1.10 Billion	-9.29%
2022-12-31	CN¥8.32 Billion ≈ $1.22 Billion	+20.82%
2021-12-31	CN¥6.89 Billion ≈ $1.01 Billion	+181.01%
2020-12-31	CN¥2.45 Billion ≈ $358.72 Million	+864.64%
2019-12-31	CN¥254.13 Million ≈ $37.19 Million	+22.16%
2018-12-31	CN¥208.03 Million ≈ $30.44 Million	+50.62%
2017-12-31	CN¥138.12 Million ≈ $20.21 Million	+39.91%
2016-12-31	CN¥98.72 Million ≈ $14.45 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Zhejiang Orient Gene Biotech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 619606382949.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥6.18 Billion	93.06%
Common Stock	CN¥201.60 Million	3.03%
Other Comprehensive Income	CN¥143.20 Million	2.15%
Other Components	CN¥116.64 Million	1.76%
Total Equity	CN¥6.65 Billion	100.00%

Zhejiang Orient Gene Biotech Co Ltd Competitors by Market Cap

The table below lists competitors of Zhejiang Orient Gene Biotech Co Ltd ranked by their market capitalization.

Company	Market Cap
PIMCO Access Income Fund NYSE:PAXS	$658.93 Million
Merlin, Inc. NASDAQ:MRLN	$658.94 Million
Dook Media Group Limited SHE:301025	$659.00 Million
Anhui Gourgen Traffic Construction Co Ltd SHG:603815	$659.34 Million
Zheshang Development Group Co Ltd SHE:000906	$658.38 Million
Wiscom System Co Ltd SHE:002090	$658.27 Million
Sunny Loan Top Co Ltd SHG:600830	$658.17 Million
Sunmax Biotechnology Co Ltd TWO:4728	$658.04 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Zhejiang Orient Gene Biotech Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 7,436,071,401 to 6,645,091,305, a change of -790,980,096 (-10.6%).
Net loss of 529,022,760 reduced equity.
Dividend payments of 16,631,227 reduced retained earnings.
Share repurchases of 276,947,754 reduced equity.
Other comprehensive income increased equity by 143,198,098.
Other factors decreased equity by 111,576,453.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥-529.02 Million	-7.96%
Dividends Paid	CN¥16.63 Million	-0.25%
Share Repurchases	CN¥276.95 Million	-4.17%
Other Comprehensive Income	CN¥143.20 Million	+2.15%
Other Changes	CN¥-111.58 Million	-1.68%
Total Change	CN¥-	-10.64%

Book Value vs Market Value Analysis

This analysis compares Zhejiang Orient Gene Biotech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.66x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 20.39x to 0.66x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CN¥1.09	CN¥22.33	x
2017-12-31	CN¥0.88	CN¥22.33	x
2018-12-31	CN¥1.34	CN¥22.33	x
2019-12-31	CN¥1.66	CN¥22.33	x
2020-12-31	CN¥12.40	CN¥22.33	x
2021-12-31	CN¥47.62	CN¥22.33	x
2022-12-31	CN¥48.60	CN¥22.33	x
2023-12-31	CN¥36.85	CN¥22.33	x
2024-12-31	CN¥33.79	CN¥22.33	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Zhejiang Orient Gene Biotech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.96%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -63.90%
• Asset Turnover: 0.10x
• Equity Multiplier: 1.22x
Recent ROE (-7.96%) is below the historical average (30.95%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	36.09%	19.55%	0.76x	2.44x	CN¥25.76 Million
2017	24.99%	14.88%	0.86x	1.94x	CN¥20.01 Million
2018	32.52%	22.87%	0.85x	1.68x	CN¥45.27 Million
2019	32.62%	22.35%	1.02x	1.44x	CN¥56.93 Million
2020	68.57%	51.37%	0.91x	1.46x	CN¥1.43 Billion
2021	71.75%	48.38%	1.13x	1.31x	CN¥4.23 Billion
2022	25.33%	23.58%	0.82x	1.31x	CN¥1.25 Billion
2023	-5.35%	-48.48%	0.09x	1.21x	CN¥-1.14 Billion
2024	-7.96%	-63.90%	0.10x	1.22x	CN¥-1.19 Billion

Industry Comparison

This section compares Zhejiang Orient Gene Biotech Co Ltd's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $1,347,771,891
Average return on equity (ROE) among peers: 27.99%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Zhejiang Orient Gene Biotech Co Ltd (688298)	CN¥6.49 Billion	36.09%	0.16x	$658.74 Million
Shanghai Kehua Bio-Engineering Co Ltd (002022)	$4.98 Billion	-4.70%	0.37x	$449.34 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223)	$137.01 Million	27.64%	0.98x	$4.30 Billion
Double Medical Technology Inc (002901)	$441.78 Million	42.71%	0.27x	$2.63 Billion
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932)	$1.42 Million	98.49%	2.27x	$577.41 Million
Lepu Medical Tech Beijing (300003)	$1.76 Billion	16.64%	0.06x	$3.87 Billion
INKON Life Technology Co Ltd (300143)	$810.78 Million	0.80%	0.23x	$1.23 Billion
Edan Instruments Inc (300206)	$2.01 Billion	8.07%	0.19x	$1.26 Billion
Guangdong Biolight Meditech Co Ltd (300246)	$89.93 Million	36.68%	0.42x	$685.28 Million
Beijing Leadman Biochemistry Co Ltd (300289)	$105.32 Million	39.32%	0.45x	$534.16 Million
Sinocare Inc (300298)	$3.14 Billion	14.20%	0.47x	$1.36 Billion

About Zhejiang Orient Gene Biotech Co Ltd

SHG:688298 China Medical Devices

Market Cap

$658.74 Million

CN¥4.50 Billion CNY

Market Cap Rank

#11160 Global

#3323 in China

Share Price

CN¥22.33

Change (1 day)

+0.68%

52-Week Range

CN¥21.90 - CN¥29.94

All Time High

CN¥221.47